Stocks Health care RXRX
NASDAQ · Health careRecursion Pharmaceuticals, Inc. (RXRX)
Recursion Pharmaceuticals, Inc. brought in $68.2M of revenue over the twelve months to September 30, 2026, up 56.2% from a year earlier. It posted a net loss of $475.7M. In fiscal 2025 capital spending exceeded operating cash flow by $378.3M. At September 30, 2026 it held $549.9M in cash against $11.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 2, 2026.
Key facts about Recursion Pharmaceuticals, Inc.
- Net worth
- Recursion Pharmaceuticals, Inc. has a market value (market cap) of $1.9B at the latest share price, and shareholders' equity of $905.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $74.7M (+26.9% year on year), with a net loss of $644.8M. Over the 12 months to September 30, 2026: revenue $68.2M, net loss $475.7M.
- Cash flow
- In fiscal 2025 operations used $371.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 2, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Recursion Pharmaceuticals, Inc.'s next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Recursion Pharmaceuticals, Inc. does
Recursion Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker RXRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $74.7M | -$644.8M | -$1.44 | -$378.3M |
| 2024 | $58.8M | -$463.7M | -$1.69 | -$372.9M |
| 2023 | $44.6M | -$328.1M | -$1.58 | -$299.7M |
| 2022 | $39.8M | -$239.5M | -$1.36 | -$120.6M |
| 2021 | $10.2M | -$186.5M | -$1.49 | -$198.4M |
| 2021 | $4M | -$87M | -$3.99 | -$51.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where RXRX ranks in Health care
Latest SEC filings
What Recursion Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 2, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 258% to $18.6M versus the same quarter last year; diluted EPS -$0.22 versus -$0.36.
- November 2, 2026
- October 15, 2026
- September 21, 2026Material agreement8-KRecursion amended its master agreement with Tempus AI and licensed its TxFM RNA model to Tempus for $12,000,000.
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 60% to $7.7M versus the same quarter last year; diluted EPS -$0.25 versus -$0.41.
- August 5, 2026
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- July 29, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Recursion Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $701.2K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 3, 2026 | Borgeson BlakeDirector | Soldpre-planned (10b5-1) | 40,000 | $155.2K |
| November 2, 2026 | Hassan FredDirector | Received as pay | 156,658 | - |
| October 6, 2026 | Hershberg RobertDirector | Exercised options | 25,000 | $55.5K |
| October 6, 2026 | Hershberg RobertDirector | Soldpre-planned (10b5-1) | 25,000 | $125K |
| October 6, 2026 | Borgeson BlakeDirector | Soldpre-planned (10b5-1) | 50,000 | $242K |
| October 1, 2026 | Li Dean YDirector | Received as pay | 3,378 | - |
| October 1, 2026 | Dar ZavainDirector | Received as pay | 4,607 | - |
| September 15, 2026 | Taylor Ben RChief Financial Officer | Shares withheld for tax | 5,396 | $18.4K |
Who owns RXRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| ARK Investment Management LLC13G, passive with 1 related filers | 7.25% | February 3, 2026 |
| Vanguard Portfolio Management13G, passive | 5.97% | July 31, 2026 |
| Vanguard Capital Management13G, passive | 5.09% | July 31, 2026 |
Largest institutional holders
Insiders
12 insiders reported holding 13,660,193 shares in total, about $48.5M at the last price.
| Holder | Shares |
|---|---|
| Borgeson BlakeDirector | 6,068,287 |
| Khan NajatCEO and President, Director | 2,072,890 |
| Li Dean YDirector | 1,476,707 |
| Taylor Ben RChief Financial Officer | 1,071,462 |
| Hallett DavidChief Scientific Officer | 1,043,837 |
| Gibson ChristopherDirector | 883,735 |
| Dar ZavainDirector | 245,371 |
| Michor FranziskaDirector | 215,477 |
| Hershberg RobertDirector | 162,156 |
| Hassan FredDirector | 156,658 |
Questions about RXRX
What does Recursion Pharmaceuticals, Inc. do?
Recursion Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as RXRX. Its shares trade on NASDAQ under the ticker RXRX.
What is Recursion Pharmaceuticals, Inc.'s net worth?
Recursion Pharmaceuticals, Inc. has a market value (market cap) of $1.9B at the latest share price, and shareholders' equity of $905.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Recursion Pharmaceuticals, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $475.7M on revenue of $68.2M.
How much revenue does Recursion Pharmaceuticals, Inc. make?
Over the twelve months to September 30, 2026 Recursion Pharmaceuticals, Inc. reported revenue of $68.2M. That is 56.2% more than a year earlier.
When did Recursion Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 2, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 4, 2026.
When is Recursion Pharmaceuticals, Inc.'s next earnings report?
Recursion Pharmaceuticals, Inc.'s next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare RXRX with
Follow RXRX
Get an email when Recursion Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Recursion Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.